Naylor NR, et al. Quantifying the primary and secondary effects of antimicrobial resistance on surgery patients: Methods and data sources for empirical estimation in England. Front Public Health. 2022;10:803943.

Article  PubMed  PubMed Central  Google Scholar 

Anesi JA, et al. Impact of donor multidrug-resistant organisms on solid organ transplant recipient outcomes. Transpl Infect Dis J Transpl Soc. 2022;24:e13783.

Article  Google Scholar 

Akash MSH, Rehman K, Fiayyaz F, Sabir S, Khurshid M. Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies. Arch Microbiol. 2020;202:953–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nanayakkara AK, et al. Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. CA Cancer J Clin. 2021;71:488–504.

Article  PubMed  Google Scholar 

Wang Y, Luo Q, Xiao T, Zhu Y, Xiao Y. Impact of Polymyxin Resistance on Virulence and Fitness among Clinically Important Gram-Negative Bacteria. Engineering. 2022;13:178–85.

Article  Google Scholar 

Righi E, et al. ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery. Clin Microbiol Infect. 2023;29:463–79.

Article  CAS  PubMed  Google Scholar 

Mühlen S, Dersch P. Anti-virulence Strategies to Target Bacterial Infections. In: Stadler M, Dersch P, editors. How to Overcome the Antibiotic Crisis. Cham: Springer International Publishing; 2015. p. 147–83.

Lee B, Boucher HW. Targeting antimicrobial-resistant bacterial respiratory tract pathogens: it is time to “get smart.”. Curr Opin Pulm Med. 2015;21:293–303.

Article  CAS  PubMed  Google Scholar 

Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov. 2010;9:117–28.

Article  CAS  PubMed  Google Scholar 

Uusitalo P, et al. The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo. J Antibiot. 2017;70:937–43.

Article  CAS  Google Scholar 

Fasciano AC, Shaban L, Mecsas J. Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target. In: Sandkvist M, Cascales E, Christie PJ, editors. EcoSal Plus. 2019;8:ecosalplus.ESP-0032-2018.

Lyons BJE, Strynadka NCJ. On the road to structure-based development of anti-virulence therapeutics targeting the type III secretion system injectisome. MedChemComm. 2019;10:1273–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

François B, et al. New Strategies Targeting Virulence Factors of Staphylococcus aureus and Pseudomonas aeruginosa. Semin Respir Crit Care Med. 2017;38:346–58.

Article  PubMed  Google Scholar 

Czaplewski L, et al. Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–51.

Article  CAS  PubMed  Google Scholar 

Yap CH, Tay ST, Chee CF. Indole Derivative (UM-3E) as an Antimicrobial and Antivirulence Strategy for the Prevention of Staphylococcus aureus Biofilm-associated Infections. Int J Infect Dis. 2023;130:S115–6.

Article  Google Scholar 

Rezzoagli C, Archetti M, Mignot I, Baumgartner M, Kümmerli R. Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa. Schulenburg H, editor. PLOS Biol. 2020;18:e3000805.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bondareva NE, et al. Preventative treatment with Fluorothiazinon suppressed Acinetobacter baumannii-associated septicemia in mice. J Antibiot. 2022;75:155–63.

Article  CAS  Google Scholar 

Koroleva EA, et al. Fluorothiazinon inhibits the virulence factors of uropathogenic Escherichia coli involved in the development of urinary tract infection. J Antibiot. 2023;76:279–90.

Article  CAS  Google Scholar 

Tsarenko SV, et al. A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia. J Antibiot. 2023;76:397–405.

Article  CAS  Google Scholar 

Savitskii MV, et al. Pharmacokinetics, quorum-sensing signal molecules and tryptophan-related metabolomics of the novel anti-virulence drug Fluorothiazinon in a Pseudomonas aeruginosa-induced pneumonia murine model. J Pharm Biomed Anal. 2023;236:115739.

Article  CAS  PubMed  Google Scholar 

Moskaleva NE, Baranov PA, Mesonzhnik NV, Appolonova SA. HPLC–MS/MS method for the simultaneous quantification of desmethylmebeverine acid, mebeverine acid and mebeverine alcohol in human plasma along with its application to a pharmacokinetics study. J Pharm Biomed Anal. 2017;138:118–25.

Article  CAS  PubMed  Google Scholar 

Sheng Y, et al. Systematic Evaluation of Dose Proportionality Studies in Clinical Pharmacokinetics. Curr Drug Metab. 2010;11:526–37.

Article  CAS  PubMed  Google Scholar 

Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat. 2009;8:38–49.

Article  PubMed  Google Scholar 

Jager NGL, Van Hest RM, Lipman J, Roberts JA, Cotta MO. Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. Expert Rev Clin Pharmacol. 2019;12:623–34.

Article  CAS  PubMed  Google Scholar 

Liu P, Müller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents. 2002;19:285–90.

Article  CAS  PubMed  Google Scholar 

Zigangirova NA, et al. Fluorothiazinon, a small-molecular inhibitor of T3SS, suppresses salmonella oral infection in mice. J Antibiot. 2021;74:244–54.

Article  CAS  Google Scholar 

Koziolek M, et al. The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. Eur J Pharm Sci. 2019;134:31–59.

Article  CAS  PubMed  Google Scholar 

Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic Circulation: Physiological, Pharmacokinetic and Clinical Implications. Clin Pharmacokinet. 2002;41:751–90.

Article  CAS  PubMed  Google Scholar 

Wagenlehner FME, Weidner W, Naber KG. Pharmacokinetic Characteristics of Antimicrobials and Optimal Treatment of Urosepsis. Clin Pharmacokinet. 2007;46:291–305.

Article  CAS  PubMed  Google Scholar